Patents by Inventor Narges TAFRESHI

Narges TAFRESHI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROCESSES FOR SYNTHESIS OF ALPHA-EMITTING RADIOPHARMACEUTICALS
    Publication number: 20230382819
    Abstract: The present disclosure provides processes for the preparation of alpha emitting radiopharmaceutical compositions, in particular DOTATATE complexes of alpha emitting radionuclides, as well as use of such prepared compositions in the treatment of cancers.
    Type: Application
    Filed: October 14, 2021
    Publication date: November 30, 2023
    Inventors: David L. MORSE, Thaddeus J. WADAS, Darpan PANDYA, Narges TAFRESHI, Mikalai BUDZEVICH
  • RADIOTHERAPEUTIC AND COMPANION IMAGING AGENTS TO TARGET MC1R
    Publication number: 20230211022
    Abstract: The subject matter disclosed herein relates generally to cancer therapy and to anticancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target MC1R and their use in the treatment of cancer. Methods of screening for MC1R targeted agents are also disclosed.
    Type: Application
    Filed: July 6, 2022
    Publication date: July 6, 2023
    Inventors: David MORSE, Robert GILLIES, Mark MCLAUGHLIN, Thaddeus WADAS, Hyun Joo KIL, Narges TAFRESHI
  • TUMOR TARGETED FLUORESCENCE GUIDANCE FOR INTRAOPERATIVE MARGIN ASSESSMENT
    Publication number: 20230115540
    Abstract: Disclosed are novel detectable imaging agents that can bind to a novel biomarker for cancer and methods of their use in the resection of a tumor.
    Type: Application
    Filed: March 8, 2021
    Publication date: April 13, 2023
    Inventors: David MORSE, Marie Catherine LEE, Narges TAFRESHI, Daruka MAHADEVAN
  • Radiotherapeutic and companion imaging agents to target MC1R
    Patent number: 11406723
    Abstract: The subject matter disclosed herein relates generally to cancer therapy and to anti-cancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target MC1R and their use in the treatment of cancer. Methods of screening for MC1R targeted agents are also disclosed.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: August 9, 2022
    Inventors: David Morse, Robert Gillies, Mark Mclaughlin, Thaddeus Wadas, Hyun Joo Kil, Narges Tafreshi
  • RADIOTHERAPEUTIC AND COMPANION IMAGING AGENTS TO TARGET MC1R
    Publication number: 20200108159
    Abstract: The subject matter disclosed herein relates generally to cancer therapy and to anti-cancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target MC1R and their use in the treatment of cancer. Methods of screening for MC1R targeted agents are also disclosed.
    Type: Application
    Filed: September 18, 2019
    Publication date: April 9, 2020
    Inventors: David MORSE, Robert GILLIES, Mark MCLAUGHLIN, Thaddeus WADAS, Hyun Joo KIL, Narges TAFRESHI
  • RADIOTHERAPEUTIC AND COMPANION IMAGING AGENTS TO TARGET MC1R
    Publication number: 20180126013
    Abstract: The subject matter disclosed herein relates generally to cancer therapy and to anti-cancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target MC1R and their use in the treatment of cancer. Methods of screening for MC1R targeted agents are also disclosed.
    Type: Application
    Filed: May 6, 2016
    Publication date: May 10, 2018
    Inventors: David MORSE, Robert GILLIES, Mark MCLAUGHLIN, Thaddeus WADAS, Hyun Joo KIL, Narges TAFRESHI